Open access
Sep 2026
AXL drives immunotherapy resistance by modulating IL-17 in bladder cancer.
Given the persistently poor five-year survival rate (<10 %) in metastatic bladder cancer (BLCA) and the limited efficacy of conventional chemotherapy and programmed cell death protein 1 (PD-1) inhibitor monotherapy, there is an urgent need to identify novel immune targets and rational combination strategies. Therefore,...
Wen-Long Wan, Fang Wei, Lu Yang et al.
· Biochemical Pharmacology · 0 citations